Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FKB238 versus Avastin in first-line advanced/recurrent non-squamous non-small cell lung cancer
2015-004104-33Phase 3Completed
- Sponsor
- Centus Biotherapeutics
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing FKB238 + paclitaxel + carboplatin with Avastin + paclitaxel + carboplatin (2 arms). Primary endpoint: Overall response rate. Started May 2016; status: completed.
02
Drugs
bevacizumab MB02bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-004104-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004104-33.